Nxera Pharma Receives US$10 Million From Abbvie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.